Growth Metrics

Moderna (MRNA) Long-Term Deferred Tax (2021 - 2024)

Moderna (MRNA) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $81.0 million as the latest value for Q3 2024.

  • For Q3 2024, Long-Term Deferred Tax changed N/A year-over-year to $81.0 million; the TTM value through Sep 2024 reached $81.0 million, changed N/A, while the annual FY2023 figure was $81.0 million, 91.75% down from the prior year.
  • Long-Term Deferred Tax hit $81.0 million in Q3 2024 for Moderna, roughly flat from $81.0 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $1.5 billion in Q2 2023 and bottomed at $50.0 million in Q1 2021.
  • Average Long-Term Deferred Tax over 4 years is $485.5 million, with a median of $203.5 million recorded in 2021.
  • Year-over-year, Long-Term Deferred Tax soared 1089.39% in 2022 and then crashed 94.53% in 2024.
  • Moderna's Long-Term Deferred Tax stood at $326.0 million in 2021, then skyrocketed by 201.23% to $982.0 million in 2022, then crashed by 91.75% to $81.0 million in 2023, then changed by 0.0% to $81.0 million in 2024.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $81.0 million, $81.0 million, and $81.0 million for Q3 2024, Q2 2024, and Q1 2024 respectively.